[{"indications": "Indications\u00a0treatment of osteoporosis in postmenopausal\r\nwomen and in men at increased risk of fractures; treatment of corticosteroid-induced\r\nosteoporosis; see also notes above", "name": "TERIPARATIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.6 Drugs affecting bone metabolism", "6.6.1 Calcitonin and parathyroid hormone", "TERIPARATIDE"], "side-effects": "Side-effects\u00a0gastro-intestinal disorders (including nausea,\r\nreflux and haemorrhoids); palpitation; dyspnoea; headache, fatigue,\r\nasthenia, depression, dizziness, vertigo; anaemia, increased sweating,\r\nmuscle cramps, sciatica, myalgia, arthralgia; less commonly urinary disorders, hypercalcaemia; injection-site reactions; rarely hypersensitivity reactions", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/128204.htm", "doses": ["By subcutaneous injection, 20\u00a0micrograms\r\ndaily; max. duration of treatment 24 months (course not to be repeated)"], "pregnancy": "Pregnancy\u00a0avoid"}]